pharma · Influenza · Celiac Disease · BRNS
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics is a pharma organization headquartered in Harwell, GB. It trades on NYSE under ticker BRNS. Primary therapeutic focus areas include Influenza, Celiac Disease, Chronic Hepatitis B, Hepatitis B, H
Harwell, GB HQ
2016 Founded
36 Employees
Public company Type
BRNS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Harwell, GB
- Founded
- 2016
- Employees
- 36
- Programs
- 9
- Drugs
- 5
- Patents
- 0
ChAdOx1-MVA 5T4 vaccine
Phase 2 · mab · Intermediate Risk Prostate Cancer
ChAdOx1-MVA 5T4 vaccine for Intermediate Risk Prostate Cancer is a Phase 2 program (mab) at Barinthus Biotherapeutics plc. with 1 ClinicalTrials.gov record(s).
Internal code ADVANCE
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Barinthus Biotherapeutics plc.
- Phase
- Phase 2
- Modality
- mab
- Indication
- Intermediate Risk Prostate Cancer
- Status
- terminated
- Trials
- 1